Tobias Machewitz

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Correction: Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.

Correction: Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.

Journal: Ophthalmology and therapy

Published: May 13, 2026

Reply.

Reply.

Journal: Ophthalmology. Retina

Published: May 05, 2026

SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema.

SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema.

Journal: Eye (London, England)

Published: April 24, 2026

Effect of key baseline disease characteristics on aflibercept 8 mg dosing interval extension: A post hoc 96-week analysis of PULSAR.

Effect of key baseline disease characteristics on aflibercept 8 mg dosing interval extension: A post hoc 96-week analysis of PULSAR.

Journal: Ophthalmology. Retina

Published: February 24, 2026

Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.

Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.

Journal: Ophthalmology and therapy

Published: January 19, 2026

Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.

Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.

Journal: Ophthalmology and therapy

Published: January 19, 2026

Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.

Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.

Journal: JAMA ophthalmology

Published: December 18, 2025

SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degeneration.

SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degeneration.

Journal: Eye (London, England)

Published: November 27, 2025

PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in Neovascular Age-Related Macular Degeneration in Subgroups Defined by Baseline Characteristics.

PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in Neovascular Age-Related Macular Degeneration in Subgroups Defined by Baseline Characteristics.

Journal: Ophthalmology. Retina

Published: September 22, 2025

Infographic: SPECTRUM: study design of the global real-world study of aflibercept 8 mg in the treatment of neovascular age-related macular degeneration and diabetic macular edema.

Infographic: SPECTRUM: study design of the global real-world study of aflibercept 8 mg in the treatment of neovascular age-related macular degeneration and diabetic macular edema.

Journal: Eye (London, England)

Published: September 15, 2025

Adherence to Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: 24-Month Results from the ANDROMEDA Study.

Adherence to Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: 24-Month Results from the ANDROMEDA Study.

Journal: Ophthalmology. Retina

Published: August 05, 2025

Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration: XTEND at 3 Years.

Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration: XTEND at 3 Years.

Journal: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde

Published: March 17, 2025

Showing 1-12 of 31

Last Updated: 09/26/2026